Meta rejected your Ayurveda ad: what breaks, and how to rewrite it

If you sell Ayurvedic products or supplements in India, ad rejections are not an occasional annoyance, they are a standing cost. The reflex fix is to soften the copy until nothing is being claimed at all, which passes review and sells nothing. That is the wrong trade, and it is avoidable.

This piece describes published platform policy and published Indian regulation. It is not legal advice. Your product's licence category determines which rulebook you sit under, and you should confirm your specific claims with your own compliance or legal counsel before running them.

You are under three rulebooks at once

Most rejection confusion comes from treating this as one problem. It is three, and they can disagree.

• Meta's advertising policy, which is global and more conservative than Indian product-labelling law. Its health and wellness standard restricts how health products may be advertised, its personal health policy governs how you may portray a viewer's condition, and its deceptive practices standard covers unsubstantiated and exaggerated outcomes.
• Indian product regulation, which is different depending on how your product is licensed.
• ASCI and the Consumer Protection Act, which govern the message and the messenger, including anyone you pay to talk about you.

A claim can be legal on your bottle and disallowed in your ad. That is not a contradiction, it is two regulators with different remits.

Which Indian rulebook you sit under depends on your licence

If you hold an ASU licence (Ayurveda, Siddha, Unani)

Your labelling follows the Drugs and Cosmetics Rules and your advertising sits under the Drugs and Magic Remedies (Objectionable Advertisements) Act. In an announcement covered by NutraIngredients in May 2024, the Ministry of AYUSH made two points that catch a lot of brands. First, AYUSH products are not permitted to claim nutraceutical value, because nutraceuticals are a separate FSSAI category with its own rules. Second, the ministry does not grant manufacturing licences or approvals for AYUSH drugs, so "approved by the Ministry of AYUSH" is not a claim available to you; a state licensing authority permission is not a ministry approval, and the ministry said such a claim on a label or advertisement would attract legal action. The same advisory named "100% safe", "free from side effects", "guaranteed treatment" and "permanent cure" as misleading.

If you hold an FSSAI licence (nutraceutical, health supplement)

You sit under the Food Safety and Standards (Health Supplements, Nutraceuticals...) Regulations 2022 and the Advertising and Claims Regulations 2018. As the law firm Cyril Amarchand Mangaldas sets out, claims about reducing the risk of diseases not listed in the relevant Schedule need mandatory pre-approval from FSSAI before you market with them; claims of direct health benefit must be supported by statistically significant results from well-designed human intervention studies published in reputable journals; and all claims in advertising, including influencer content, must be consistent with what is on the product label. Section 53 of the FSS Act carries a penalty of up to ₹10 lakh for misleading food advertisements.

The practical read: if your ad copy makes a claim your label cannot make, you have a regulatory exposure regardless of whether Meta approves the ad.

What Meta's auto-review actually catches

Read the rejection reason before you rewrite, because Meta uses similar wording for several distinct policies and each has a different fix. A health-claim rejection, a personal-attributes rejection and a misleading-content rejection are not the same problem.

The consultancy Wittelsbach AI publishes a useful breakdown of the phrase patterns that trigger Ayurveda rejections, and it matches our own experience running these accounts. The recurring shapes are:

• Naming a disease and implying management or treatment.
• Promising a body-system outcome, immunity being the most common in Indian supplements.
• Promising symptom resolution on a timeline.
• Comparing your product to a regulated drug class.
• Quoting an outcome percentage with no cited source.

Visuals count too. Before-and-after body imagery, medical diagrams, pill bottles and white coats push an ad toward the medical reading of the policy even when the copy is clean.

Specificity beats vagueness, and it is not close

Here is the counter-intuitive part. Brands respond to rejections by removing detail: "supports overall wellness", "goodness of nature", "holistic balance". That copy still implies a health outcome, so it does not reliably pass, and it certainly does not sell, because it is indistinguishable from every competitor.

The move that works is the opposite: replace the unverifiable outcome claim with a specific, checkable, non-therapeutic fact. Where the ingredient comes from. Who made it. How it was processed. How much of it is in the pack. What tradition it belongs to and what text describes it. None of those are health claims, all of them are more persuasive than "wellness", and they are the things a buyer cannot verify about your competitor.

We have the numbers on this. Barosi was not an Ayurveda brand, but the mechanism is identical and the data is unusually clean. Its ads claimed purity in a category where every label claims purity and almost none of it is checkable at the moment of scroll. Replacing the claim with a named farm, a visible process and a face moved ROAS from a loss-making 0.6× to 3.8×, halved CAC, and lifted on-site conversion from 0.8% to 6.8% in three months. Specificity is the mechanism: a named farm can be checked in a way the word pure cannot, and checkable claims are what let a premium price survive a cold audience.

Amyra Farms is the Ayurvedic version. Premium Ayurvedic positioning sailed straight over cold audiences, because Ayurveda asks a buyer to accept a claim about how something works and a stranger has no reason to extend that credit to a brand they met a moment earlier. The rebuild used founder-led video for credibility and ingredient-led hooks for purity, heritage and function, split across a real full funnel. CAC dropped more than 50% in three months and ROAS doubled. Founder video works here for a specific reason: a person on camera making a claim is accountable for it in a way a product shot is not.

Rewrites that keep the selling power

• Outcome to origin. Instead of promising what the product does to a body system, say where the raw material comes from, who grows it, and how it is processed. Single-origin, cold-pressed, stone-ground, harvest month.
• Claim to composition. State quantity and form. How many milligrams, what extract ratio, what else is or is not in the pack. Facts about the product are not claims about the buyer.
• Cure to ritual. Describe when and how the product is used in a daily routine rather than what it resolves. Usage occasions sell without promising outcomes.
• Modern authority to traditional authority. Naming the classical tradition an ingredient belongs to is a heritage statement. Implying clinical efficacy is a health claim. Keep the two apart, and if a qualified practitioner formulated it, name them and their qualification rather than saying "doctor recommended".
• Never quote a number without its source. "9 out of 10 users" with nothing behind it is the fastest rejection on this list and, under the FSSAI rules above, the riskiest one off-platform too.

Influencers are a separate and larger exposure

If you pay creators, ASCI's influencer guidelines apply. As Cyril Amarchand Mangaldas summarises, a disclosure label is mandatory wherever a material connection exists, and material connection is defined broadly enough to include free product, discounts, trips and barter, not just cash. Labels must be hard to miss rather than buried in hashtags. Crucially for this category, ASCI added a requirement that health and wellness influencers hold relevant qualifications, such as a medical degree or certified nutritionist or dietician credentials, and disclose them prominently.

Both the brand and the influencer carry responsibility, and endorsers are explicitly liable under the Consumer Protection Act, with the CCPA empowered to order ads modified or discontinued and to impose penalties. In practice this means an influencer improvising a disease claim on camera creates your exposure, not just theirs. Script review is not bureaucracy here, it is the control.

Appeals, and when not to bother

Appeal when the copy is genuinely free of outcome claims and the automated system has misread a heritage or sourcing statement. Keep the appeal short and factual: state that the ad references ingredient sourcing and traditional context rather than health outcomes, and cite your licence. Do not appeal when the copy really does contain a trigger, even a subtle one, because a failed appeal costs you days you could have spent running a rewritten ad. Most rejected Ayurveda ads we review do contain a trigger. It is usually one word.

Compliance and persuasion pull in the same direction more often than anyone expects. The claim you cannot prove is also the claim nobody believes.

Getting this right is a creative problem as much as a legal one, which is where our creative and content work sits, and the category context is on our nutrition page. If the ads are approved and sales still are not moving, the blockage may be on-site instead: that is what happened at Butterfly Ayurveda, where demand was never the missing piece.